Biodesign Innovation Labs is a healthtech medical device startup based in Bengaluru, India, that develops low-cost respiratory and ventilation devices for patients in India and other low-resource settings.

This Startup Deep Dive explains what Biodesign Innovation Labs does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Biodesign Innovation Labs in Brief

• What it is: Biodesign Innovation Labs is an Indian Respiratory medical devices company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company makes RespirAID, a mechanical ventilation device that the company says can stand in for prolonged manual bag-valve-mask ventilation and is portable for patient transport.
• RespAP is a CPAP-type respiratory support device giving oxygen therapy to children in respiratory distress, aimed at both low-resource settings and tertiary hospitals.
• CornealX, an AI-based healthcare tool, is described as part of the product line.
• Funding: Not disclosed in public sources reviewed.

Biodesign Innovation Labs Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Biodesign Innovation Labs?

Biodesign Innovation Labs operates in the Respiratory medical devices space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Biodesign Innovation Labs.

• The company makes RespirAID, a mechanical ventilation device that the company says can stand in for prolonged manual bag-valve-mask ventilation and is portable for patient transport.
• RespAP is a CPAP-type respiratory support device giving oxygen therapy to children in respiratory distress, aimed at both low-resource settings and tertiary hospitals.
• CornealX, an AI-based healthcare tool, is described as part of the product line.

The Origin Story of Biodesign Innovation Labs

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Adithya Pasupuleti, Gautham Pasupuleti.
• The company was started by brothers Adithya and Gautham Pasupuleti, with Gautham serving as CEO and managing director; one database lists the founders differently (reports differ).
• The founders spotted gaps in respiratory and paediatric care through hospital visits across India, especially ICU, emergency and paediatric units, and use a design-thinking approach.
• It was incubated at IKP Eden in Bengaluru.
• Its stated aim is reducing mortality and illness among children under five through affordable ventilators for the Indian market.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Respiratory medical devices sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2017: CAMTech National Jugaadathon award (reported).
• 2019: RespAP in clinical pilot with a planned 2019 launch; RespirAID targeted for launch in 2020 (stated in April 2019).
• October 2019: presented RespirAID at a healthcare conference in Berlin (company-stated).
• 2019-2020: shortlisted in the Qualcomm Design in India 2019 Challenge top 10.
• March 2020: during the COVID period the company said it needed close to Rs 10 crore to set up large-scale manufacturing of RespirAID.
• 2021: Pandemic Response Prize in the Cisco Global Problem Solver Challenge.

Biodesign Innovation Labs Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported support from CAMTech (MGH), KBITS Elevate 100, DST Nidhi Prayas (via IKP Eden), BIRAC BIG (via IKP) and the Government of Karnataka; amounts not disclosed in sources read.
• Company said in 2020 it needed close to Rs 10 crore for manufacturing scale-up.

How Does Biodesign Innovation Labs Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• The company sells medical devices and plans to reach users through government agencies, distributors and private hospital chains (company-stated).

The Numbers: Biodesign Innovation Labs Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for Biodesign Innovation Labs were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for Biodesign Innovation Labs

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Targets India and other developing countries, with stated aims to enter the US and Europe (company-stated).
• The company cited the Indian respiratory therapeutic devices market as over USD 8 billion (stated in 2019).

Technology and Product at Biodesign Innovation Labs

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• RespirAID is a positive pressure mechanical ventilation device; internal design not described in sources read.

Team and Culture at Biodesign Innovation Labs

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Gautham Pasupuleti is CEO and managing director; Adithya Pasupuleti is a co-founder.
• Early team included embedded, mechanical design and robotics engineers (2019).

Biodesign Innovation Labs Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Biodesign Innovation Labs vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Biodesign Innovation Labs

• Small team: one database lists headcount of three.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Biodesign Innovation Labs Growth Outlook: What to Watch

• The company said it aims to enter US and European markets alongside India and other developing countries.
• It said it plans partnerships with government agencies, distributors and private hospital chains.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Biodesign Innovation Labs can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Biodesign Innovation Labs Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Biodesign Innovation Labs

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Biodesign Innovation Labs.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Biodesign Innovation Labs

Studying a company in the Respiratory medical devices space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Biodesign Innovation Labs.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Biodesign Innovation Labs as a Startup

• Customer clarity: Can Biodesign Innovation Labs name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Biodesign Innovation Labs is part of India’s growing Respiratory medical devices ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Biodesign Innovation Labs FAQs: Frequently Asked Questions

What is Biodesign Innovation Labs?

Biodesign Innovation Labs is a healthtech medical device startup based in Bengaluru, India, that develops low-cost respiratory and ventilation devices for patients in India and other low-resource settings. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Biodesign Innovation Labs?

Biodesign Innovation Labs was founded by Adithya Pasupuleti, Gautham Pasupuleti, and the company reports a founding year of 2017.

How much funding has Biodesign Innovation Labs raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Biodesign Innovation Labs make money?

Biodesign Innovation Labs earns revenue from its Respiratory medical devices products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Biodesign Innovation Labs?

Competitors of Biodesign Innovation Labs depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Biodesign Innovation Labs?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: KoinX — KoinX: crypto tax startup that raised a $1.5M seed in 2022 | Salt — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.